Join Dr. Fozia Saleem, CEO of Magnitude Biosciences, for an essential discussion on how whole-organism biology, high-throughput imaging, and automated machine learning platforms are solving the single greatest challenge in pharmaceutical drug discovery: translational failure. While in vitro cell models and in silico AI predictions offer speed, they fail to replicate complex biological systems, neuromuscular junctions, and full-organism aging pathways. Drawing on over two decades of leadership across pharma, FMCG, and life sciences—including executive roles at GSK, BAT, and Broughton—Fozia shares how Magnitude Biosciences utilizes patented automated imaging engines (such as WormGazer™ and VivoScan™) to track C. elegans healthspan, lifespan, and neurodegeneration at scale. In this episode, she breaks down how high-throughput in vivo data helps researchers "fail fast and fail cheap", turning academic scientific breakthroughs into a scalable commercial business.
🎯 Insights You’ll Learn:
The Translational Bottleneck in Drug Discovery: Why traditional cell cultures and organoids fail to model complex systemic diseases, host-microbe interactions, and organismal aging.
Automated Whole-Organism Screening at Scale: Utilizing C. elegans as a high-throughput model to screen thousands of compounds in weeks—measuring healthspan and lifespan simultaneously at a fraction of mammalian testing costs.
Machine Learning at the Edge of Biology: How Magnitude Biosciences’ patented platforms (WormGazer™ and VivoScan™) use computer vision and AI algorithms to analyze microscopic organismal movement and health indicators.
Empowering Diverse Leadership in Science: Fozia’s personal journey as the first in her family to enter higher education, earning her PhD from Edinburgh, and her commitment to mentoring female founders through platforms like The Lifted Project / The Whole Point.
🌍 Why This Matters:
Over 90% of prospective therapeutics fail in clinical trials, primarily because early-stage screening relies heavily on isolated cell cultures that do not capture whole-body biological complexity. In age-related conditions—such as Alzheimer's, Parkinson's, and sarcopenia—aging is an organism-wide event that cannot be duplicated in a petri dish. Dr. Fozia Saleem is revolutionizing this preclinical paradigm. By combining automated computer vision with fast-aging living organisms, Magnitude Biosciences gives biotech and pharma teams real in vivo insights early in the pipeline—reducing clinical failure rates, saving millions in R&D capital, and accelerating life-extending therapeutics to patients.
👤 Expert Background:
CEO of Magnitude Biosciences, leading the CRO delivering automated, AI-powered whole-organism testing platforms for longevity, FMCG, and drug discovery.
🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era.
💡 Perfect For:
Pharma and biotech executives, longevity researchers, deep-tech venture capitalists, CRO leaders, life sciences commercial leads, female founders, and AI-in-drug-discovery engineers.
🚀 Timely Topic:
As the global biotech sector shifts toward longevity medicine, healthspan optimization, and AI-driven drug design, obtaining rapid, cost-effective in vivo validation is a critical market priority. Dr. Fozia Saleem provides a masterclass on transforming complex biological innovation into a thriving, venture-backed enterprise.
Subscribe for more global founder conversations from GSD Venture Studios: https://gsdvs.com
#Biotech #DrugDiscovery #MagnitudeBiosciences #FoziaSaleem #Longevity #AIinPharma #DeepTech #GaryFowler #GSDVentureStudios
